How does chasteberry lower prolactin?

Its diterpenes activate dopamine D2 receptors in the pituitary. Dopamine is the natural brake on prolactin release, so activating those receptors reduces secretion.

Can it treat a prolactinoma?

No. Pituitary adenomas need imaging and prescription dopamine agonists. Using Vitex instead risks delaying treatment of a tumour that can affect vision.

What dose was studied?

20 to 40 mg per day of a standardised dried extract, taken once daily in the morning.

How long before anything changes?

Give it three full cycles. Trials ran about three months and the mechanism is a gradual shift in pituitary signalling.

Can I take it while breastfeeding?

No. Reducing prolactin can lower milk supply, which is the opposite of what you want.

Does it affect contraception?

Its hormonal activity means it may theoretically interfere. Do not rely on it alongside hormonal contraception without discussing it with your clinician.

Is it the same as taking vitamin B6?

No. Vitamin B6 has been studied separately for prolactin and works through a different route; the two should not be treated as interchangeable.

Outcome

Moderate Evidence

Vitex (Chasteberry) for Prolactin Regulation

Vitex is the only common supplement with credible prolactin-lowering data, appropriate for mild cyclical symptoms.

Overview

Vitex agnus-castus is the rare herbal remedy with a clearly identified endocrine target. It acts on dopamine D2 receptors in the anterior pituitary, and because dopamine is the body's main brake on prolactin release, the practical result is lower prolactin secretion. A 1993 randomised placebo-controlled trial in women with latent hyperprolactinaemia and luteal phase defect found reduced prolactin release and lengthened luteal phases. Most of the modern evidence sits one step downstream, in premenstrual syndrome, where two 2017 meta-analyses in the American Journal of Obstetrics and Gynecology found benefit for symptoms including cyclical breast pain — a prolactin-sensitive symptom. The important boundary is that this is mild, latent hyperprolactinaemia territory. Pathological hyperprolactinaemia from a pituitary adenoma requires imaging and prescription dopamine agonists, not a herbal preparation.

Verdict

Likely effective

A randomised placebo-controlled trial shows Vitex lowers prolactin release in latent hyperprolactinaemia, and meta-analyses support benefit for prolactin-sensitive premenstrual symptoms. It is not a treatment for pathological hyperprolactinaemia.

How It Works

Prolactin secretion is under tonic inhibition: dopamine released from the hypothalamus reaches the anterior pituitary and suppresses lactotroph output continuously. Vitex contains diterpenes, particularly clerodadienols, that bind and activate pituitary D2 receptors, mimicking that inhibition. This is the same receptor family targeted by prescription dopamine agonists such as bromocriptine and cabergoline, at much lower potency. Lower prolactin has knock-on effects on the cycle. Mildly raised prolactin suppresses gonadotrophin-releasing hormone pulsatility, blunting luteinising hormone and impairing corpus luteum function, which shows up as a short luteal phase and low progesterone. Reducing prolactin releases that suppression, which explains why the 1993 trial found luteal phase lengthening alongside the prolactin change. Vitex extracts also show weak binding to oestrogen and opioid receptors, of uncertain clinical relevance.

Pathways involved

Pituitary dopamine D2 receptor agonism

Lactotroph prolactin secretion

GnRH pulsatility and LH release

Luteal phase progesterone production

Weak oestrogen and opioid receptor binding

Dosing & Protocol

Trials cluster around 20 to 40 mg per day of a standardised dried extract, with the widely studied Ze 440 extract used at 20 mg daily and BNO 1095 at similar doses. Older German trials of the 1993 type used 20 mg daily of a comparable preparation. Doses of 4 mg of the highly concentrated extracts and up to 1,800 mg of crude dried fruit also appear in the literature, which makes comparing products difficult — read the extract ratio, not just the milligram figure. Take it once daily in the morning, before food, and continue through the whole cycle rather than only in the luteal phase; the mechanism is a slow shift in pituitary signalling, not an acute effect. Prolactin changes can be measured within one to three cycles, but symptom trials generally ran three months, and three full cycles is the fair test.

Scenario	Dose	Form	Timing
Standard trial dose	20-40 mg/day	Standardised dried extract (e.g. Ze 440)	Once daily, morning, before food
Latent hyperprolactinaemia trial	20 mg/day	Standardised extract	Daily for 3 months
Concentrated extracts	4-8 mg/day	High-ratio extract	Follow the product extract ratio
Crude dried fruit	up to 1,800 mg/day	Powdered fruit	Much weaker than standardised extract
Assessment period	3 full cycles	-	Symptom trials generally ran 3 months
Continuous vs luteal	Continuous daily use	-	Not cycled to the luteal phase

1
Get prolactin measured properly· Before starting
A morning fasted sample, avoiding recent breast stimulation, exercise or stress. A markedly raised level needs medical investigation, not a supplement.
2
Exclude the causes that need treatment· Before starting
Pituitary adenoma, hypothyroidism, chronic kidney disease and prolactin-raising drugs such as antipsychotics and metoclopramide all require their own management.
3
Start 20 mg of a standardised extract daily· Cycle 1
Morning, before food, every day rather than only in the second half of the cycle.
4
Track cycle length and symptoms· Cycles 1-3
Cycle length, luteal phase length if you chart, and cyclical breast pain are the practical markers of change.
5
Reassess after 3 cycles· Cycle 3
Recheck prolactin if it was raised. No change in symptoms or prolactin after three cycles means it is unlikely to help.

Evidence

The 1993 Arzneimittelforschung randomised placebo-controlled study is the direct evidence for the prolactin claim. In women with latent hyperprolactinaemia and luteal phase defect, three months of Vitex reduced prolactin release in response to thyrotropin-releasing hormone stimulation, normalised shortened luteal phases and raised mid-luteal progesterone, without changing other pituitary hormones. It is a small, old trial, but it is a placebo-controlled measurement of the exact endpoint. The two 2017 meta-analyses in the American Journal of Obstetrics and Gynecology examined Vitex in premenstrual syndrome and both found significant symptom improvement over placebo, while flagging heterogeneous preparations, small samples and a risk of publication bias. A 1976 Journal of Clinical Endocrinology and Metabolism trial of vitamin B6 in hyperprolactinaemia is linked here as adjacent evidence on the same endpoint; it examines pyridoxine rather than Vitex, and is relevant only as context for the dopaminergic hypothesis.

Best available evidence: One randomised placebo-controlled trial on prolactin, two meta-analyses on premenstrual symptoms, one adjacent trial on vitamin B6
Typical effect: Reduced prolactin release and lengthened luteal phase in latent hyperprolactinaemia
Studied dose: 20-40 mg/day standardised extract
Time to effect: 3 cycles
Boundary: Not effective or appropriate for pituitary adenoma or marked hyperprolactinaemia
Certainty of evidence: Moderate for symptoms; limited but direct for prolactin, resting on one small trial

The randomised placebo-controlled trial of Vitex in latent hyperprolactinaemia and luteal phase defect, two meta-analyses of Vitex in premenstrual syndrome, and an adjacent trial of vitamin B6 on prolactin secretion linked to this outcome.

The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis

Score: 9/10

2017

meta_analysis

n=1071

Verkaik S, Kamperman AM, van Westrhenen R +1 more

Trials with low risk of bias yielded substantially smaller effect sizes than weaker studies of Vitex agnus castus.

View source

Vitamin B6 treatment of hyperprolactinaemia: effects on prolactin secretion

Score: 4/10

1976

rct

n=12

Delitala G, Masala A, Alagna S +1 more

Pyridoxine acutely suppressed prolactin release through dopaminergic stimulation, but the effect was short-lived

View source

Vitex agnus-castus in latent hyperprolactinaemia and luteal phase defect: a randomized placebo-controlled study

Score: 6/10

1993

rct

n=52

Milewicz A, Gejdel E, Sworen H +3 more

Vitex reduced prolactin release and raised mid-luteal progesterone levels versus placebo

View source

Vitex agnus-castus for premenstrual syndrome: a systematic review and meta-analysis of randomised controlled trials

Score: 7/10

2017

meta_analysis

n=1300

Verkaik S, Kamperman AM, van Westrhenen R +1 more

Vitex extract produced a large reduction in premenstrual symptom scores versus placebo

View source

Safety

Vitex is generally well tolerated. Reported adverse effects in trials were mild and uncommon: nausea, headache, gastrointestinal upset, acne, and occasional intermenstrual spotting or changes in cycle length, which follows directly from the hormonal mechanism. Serious adverse events were not a feature of the trial literature. The cautions matter more than the side effects. Avoid in pregnancy for lack of safety data, and avoid while breastfeeding for the opposite reason to the usual one — lowering prolactin can reduce milk supply. Because it acts on dopamine receptors, Vitex should be avoided alongside dopamine agonists and dopamine antagonists including antipsychotics and metoclopramide, where it may interfere in either direction. Its weak oestrogen receptor activity means caution in hormone-sensitive cancers, and it may theoretically reduce the reliability of hormonal contraception. Anyone with markedly raised prolactin, galactorrhoea, visual field changes or absent periods needs pituitary imaging, not a herb.

Rule out a pituitary cause first

Galactorrhoea, absent periods, headaches or visual field loss with raised prolactin suggest a pituitary adenoma. That needs MRI and prescription treatment; Vitex is not an alternative and delay can cost vision.

Interactions & Conflicts

Interacts with	Severity	Mechanism	Action
Dopamine agonists (bromocriptine, cabergoline)	moderate	Additive D2 receptor agonism	Avoid combining without endocrinology advice
Antipsychotics and metoclopramide	moderate	Opposing actions at dopamine receptors; may reduce drug effect	Avoid
Breastfeeding	high	Lowering prolactin can reduce milk supply	Avoid
Pregnancy	high	No adequate safety data and hormonal activity	Avoid
Hormonal contraceptives and HRT	moderate	Weak oestrogen receptor activity and hormonal effects may interfere	Do not rely on it alongside; discuss with a clinician
Hormone-sensitive cancers	moderate	Weak oestrogenic activity	Avoid without oncology advice
In vitro fertilisation and fertility treatment	moderate	May interfere with controlled ovarian stimulation protocols	Stop before treatment cycles unless advised otherwise

References

Frequently Asked Questions

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.